BioCentury
ARTICLE | Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

Twentyeight-Seven is capitalizing on the emerging biology of RNA-binding proteins by targeting their interactions with non-coding RNAs

July 11, 2019 10:35 PM UTC

Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins.

Launched last September, the company is using an $82.8 million series A round backed by a syndicate that includes MPM Capital, Novartis Venture Fund and Sofinnova Partners to advance its lead cancer program and extend its platform to similar targets in other indications, including inflammatory diseases...